https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24542 2 cm and/or node positive. At 3.9 years median follow-up (interquartile range 3.1- 4.8), 2 patients assigned letrozole (1.1%) and 17 patients assigned observation (9.5%) had experienced an invasive breast cancer event (difference 8.4%, 95% confidence interval 3.8% to 13.0%, log-rank test P = 0.0004). Twenty-four patients (13.4%) in the observation and 14 (7.7%) in the letrozole arm experienced a DFS event (log-rank P = 0.067). Adverse events linked to oestrogen depletion, but not serious adverse events, were more common with letrozole. Conclusion: These results should be considered exploratory, but lend weight to emerging data supporting longer duration endocrine therapy for hormone receptor-positive breast cancer, and offer insight into reintroduction of AI therapy. Clinical Trials Number: Australian New Zealand Clinical Trials Registry (www.anzctr.org.au), ACTRN12607000137493]]> Wed 09 Feb 2022 15:57:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16286 Sat 24 Mar 2018 07:59:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20604 Sat 24 Mar 2018 07:55:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4802 Sat 24 Mar 2018 07:20:39 AEDT ]]>